← Back to Search

Anti-thrombotic

Thrombolytic Therapy for Ischemic Stroke

Phase 1 & 2

Waitlist Available

Research Sponsored by Baylor College of Medicine

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Anterior Circulation stroke within the last six hours

Posterior Circulation stroke within the last 12 hours

Must not have

Have clinical signs and symptoms of liver failure or elevations in AST, and ALT > 3 times the normal values

INR greater than 2.5 while on treatment with warfarin

Timeline

Screening 3 weeks

Treatment Varies

Follow Up ninety days

Awards & highlights

No Placebo-Only Group

Summary

This trial is testing the use of a GP IIb/IIIa inhibitor (abciximab) in patients with stroke.

Who is the study for?

This trial is for adults who've had a stroke affecting the brain's anterior region within 6 hours or posterior region within 12 hours. They must not have signs of non-ischemic causes like hemorrhage or tumor, severe kidney/liver issues, very low platelet counts, or be at high risk of bleeding.

What is being tested?

The study tests how well GP IIb/IIIa inhibitors work in patients with ischemic strokes. These are potent platelet inhibitors already used for heart conditions and might help when given alongside standard treatments like t-PA or thrombectomy.

What are the potential side effects?

Potential side effects may include increased risk of bleeding due to the drug's ability to prevent blood clots. This could lead to complications such as bruising easily, nosebleeds, and in rare cases more serious internal bleeding.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I had a stroke affecting the front part of my brain within the last 6 hours.

Select...

I had a stroke in the back part of my brain within the last 12 hours.

Select...

I am 18 years old or older.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I show signs of liver failure or have high liver enzyme levels.

Select...

My INR is above 2.5 while I'm on warfarin.

Select...

My PTT levels are above 75 while I'm on heparin.

Select...

I was dependent on others for daily activities before my current illness.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ ninety days

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~ninety days

This trial's timeline: 3 weeks for screening, Varies for treatment, and ninety days for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Ninety day functional outcomes

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups

Experimental Treatment

Group I: Measurement of Platelet functionExperimental Treatment1 Intervention

Patients with ischemic stroke may be given alteplase or other thrombolytic. Additionally, patients may be given IV platelet inhibitors and subjected to thrombectomy. Platelet functions are measured after intervention.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Thrombolytic Agent

2021

N/A

~490

0 / 7Eligibility criteria met